Engagement of a pharmacist in a community pharmacy hypertension management program in collaboration with a university medical center

This article was originally published here

Am J Health Syst Pharm. March 12, 2022: zxac081. doi: 10.1093/ajhp/zxac081. Online ahead of print.

ABSTRACT

DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP publishes these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and edited, but are posted online prior to technical editing and author verification. These manuscripts are not the final version of the file and will be replaced by the final article (formatted according to the AJHP style and corrected by the authors) later.

OBJECTIVE: To explore the perceptions of pharmacists and administrators who played a critical role in the design and operationalization of an integrated community pharmacist hypertension management program with the collaboration of an academic medical center and from a community pharmacy to a regional chain.

SUMMARY: Community pharmacists (n=3), ambulatory care pharmacists (n=2), medical directors (n=2), and health system (n=1) and pharmacy administrators (n=1 ) reported positive experiences with hypertension management program. Program strengths included comprehensive training by ambulatory care pharmacists, community pharmacists’ access to the electronic health record (EHR), and primary care providers receptive to patient referrals and accepting referrals from community pharmacists . All participants felt that the program had a positive outlook and that there were opportunities for expansion, such as extended hours, new locations and additional pharmacists.

CONCLUSION: Pharmacists are well placed to extend hypertension management programs from primary care clinics to local pharmacists if they have appropriate training, access to the EHR, and ongoing support from collaborating primary care offices. Further research using implementation science methods is needed to further test the scalability and reproducibility of the program among different patient populations, community pharmacies, and health systems.

PMID:35278307 | DO I:10.1093/ajhp/zxac081

Comments are closed.